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Background: Incidence of anal carcinoma (AC) is increasing and timely diagnosis is critical for efficient therapy.
However, there is a paucity of recent studies addressing clinical symptoms and physical findings of anal carcinoma.
Methods: We performed a retrospective study reviewing history, symptoms and physical findings from 86 patients
with newly diagnosed AC. We analyzed frequency of symptoms and physical findings according to T and TNM
stage and their predictive value regarding tumor stage.
Results: Most patients presented with T2 (37 %) or T3 (29 %) cancer. 85 of 86 patients were symptomatic with anal
bleeding (78 %), anal/perianal pain (63 %), weight loss (31 %) and foreign body sensation (22 %). 95 % of patients
had ≥1 finding on physical examination including a visible tumor, palpable resistance and pain/blood during digital
rectal examination. Patients with locally advanced disease (T3/T4) presented with more symptoms (p < 0.01) and
more physical findings (p = 0.04) than patients with T1/T2 disease. On multivariate regression analysis perianal pain,
painful defecation and weight loss were significantly associated with T3/T4 disease.
Conclusion: Clinical symptoms and physical findings are present in nearly all AC patients. Pain referred to the perianal
region, painful defecation and weight loss have predictive value for locally advanced disease.
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Anal carcinoma is an uncommon malignancy with an in-
cidence of 2 new cases per 100,000 per year in the USA
[1–6], comprising approximately 0.4 % of all tumors and
2.5 % of all gastrointestinal malignancies. Within the last
decades the incidence of anal carcinoma has steadily in-
creased and anal carcinoma incidence is now 2-fold
higher than 30 years ago and 4-fold higher in selected
subgroups of patients [3, 6, 7]. Risk factors associated
with anal carcinoma are the lifetime number of sexual
partners, receptive anal intercourse, cigarette smoking,
genital warts and viral infections especially human papil-
lomavirus (HPV), and human immunodeficiency virus* Correspondence: benjamin.misselwitz@usz.ch
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(http://creativecommons.org/publicdomain/ze(HIV) [8]. The increasing incidence of anal carcinoma
might reflect changes in one or more of the risk factors
mentioned above and might follow an increase in infec-
tion rates of HPV and HIV.
Timely diagnosis of anal carcinoma is critical, since for
the treatment of early cancer highly effective and function
preserving radio-(chemo) therapy is available. In contrast,
the options for advanced and metastasized carcinoma are
limited [1, 4, 9]. Clinical symptoms in the assessment anal
cancer have only been insufficiently studied. Previous
studies with a limited number of patients identified rectal
bleeding (45 %), anorectal pain (20–35 %) and the sensa-
tion of a rectal mass (20–35 %) as the most prevalent
complaints [10–14] with approximately 20 % of patients
being free of symptoms in the largest study [10]. Clinical
findings of anal carcinoma have not been summarized in
detail. An association of symptoms or findings with early
or an advanced disease has to the best of our knowledgeis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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and 1986 and no recent data are available. In the interven-
ing time medical practice has seen important changes
including a massive increase in endoscopic evaluations of
the colon. Following current guidelines, staging procedure
of anal carcinoma now includes MRI and/or endosono-
graphy [1, 9], techniques unavailable 30 years ago. Con-
sidering these changes and the dramatic increase of
anal carcinoma incidence, clinical presentation might
differ now compared to the 1970s and the 1980s.
We therefore performed a systematic study of present-
ing symptoms and physical findings in patients with
newly diagnosed anal cancer. Signs, symptoms and find-
ings that differed for early and advanced anal carcinoma
were identified.
Methods
We performed a retrospective analysis of all patients
referred to Triemli-Hospital, a tertiary care center and
teaching hospital in Zürich, Switzerland from 1999 until
2013 for treatment of anal carcinoma. Patients were
identified by an automated search within the internal
clinical information system. Histological evidence of anal
carcinoma was a requirement for inclusion and all pa-
tients with rectal carcinoma were excluded. We only
considered symptoms and findings from the first presen-
tation of anal carcinoma and recurrent anal carcinoma
cases were excluded.
The study protocol was approved by the local ethics com-
mittee of Zurich county (Registration KEK-ZH 2010–0555).
The study was performed according to the Declaration of
Helsinki.
Data collection
All relevant parameters regarding the initial clinical assess-
ment including patient demographics, a detailed personal
history, local and systemic symptoms, findings on physical
examinations, and results of investigations (endoscopy with
histology and staging investigations including CT, MRI and
endosonography) were extracted from the documented pa-
tient history as well as from referral letters.
Tumor classification followed the 7th edition of the
American joint Committee on Cancer TNM staging [15]
with T1 referring to a tumor size <2 cm, T2: a tumor
between 2 and 5 cm, T3: a tumor >5 cm and T4 a tumor
invading adjacent organs. N1 refers to lymph node
metastasis in perirectal lymph nodes; N2 to metastasis
in unilateral internal iliac and/or inguinal lymph node(s);
and N3 to metastasis in perirectal and inguinal lymph
nodes and/or bilateral internal iliac and/or inguinal
lymph nodes. Stage I refers to a T1 tumor without
lymph node involvement or distant metastasis. Stage II
refers to a T2 or T3 tumor without lymph node or
distant metastasis. Stage III refers to either i) T1-3 withN1 without metastasis or ii) any N2 or N3 positivity
without metastasis independent of T-Stage or iii) T4
with N0 or N1 without distant metastasis. Stage IV refers
to a tumor with advanced (N3) lymph node involvement
(bilateral inguinal or bilateral internal iliac) or a tumor
with distant metastasis. During our chart review all find-
ings from all original investigations (CT, MRI and EUS)
were evaluated and the appropriate tumor stage noted.
We also differentiated between distal, middle and prox-
imal location according to i) digital rectal exam; ii) findings
reported by CT, MRI or endosonography. Distal tumors in-
cluded the anal rim/perianal region and proximal tumors
included local invasion into the rectum.
Data analysis
For each symptom and each physical finding we calculated
the frequency for patients of each T-stage and TNM-stage.
To identify differences for early and advanced carcinoma,
χ2 significance of a trend (T1 – T4 or stage I – stage IV, re-
spectively) was calculated using a generalized linear model.
To study the effect of the age at diagnosis on tumor
characteristics our cohort was divided according to the me-
dian age (62 years) into a younger age group (≤62 years)
and older age group (>62 years) and independent samples
test was used for the comparison of means. A similar com-
parison was also performed to evaluate differences between
the subgroups with proximal and distal anal carcinomas.
Multivariate logistic regression was used to analyze the
predictability of early and advanced T-stage (or TNM
stage) cancers. For this purpose T1-2 cancers (or TNM
stage I and II) were categorized as early, T3-4 (or TNM
stage III and IV) as advanced cancers. We tested clinical
symptoms, physical findings and patient demographics
such as gender, body mass index (BMI) and age at diag-
nosis as potential predictors. Potential predictors were
sorted according to their p-values. In a step-wise proced-
ure all descriptors with p-values <0.1 were eliminated
and the regression analysis was repeated. This procedure
eliminated several general descriptors including gender,
BMI and age at diagnosis and the remaining variables
with p < 0.1 and their corresponding odds ratios (OR)
are reported. Similar analyses were also performed for
the prediction of the TNM stage. All statistical analyses
were performed using SPSS software.
Results
Our electronic search identified 95 patients with anal car-
cinoma. 9 patients were excluded due to recurrent anal
cancer and the analysis was restricted to the remaining 86
patients. All carcinoma cases had conclusive histology of
anal carcinoma: 85 were squamous cell carcinoma, 10 of
these with basaloid and one with cloacogenic subtype; one
tumor was a neuroendocrine carcinoma with small cell
features. No patient with anal adenocarcinoma was treated
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for HPV was performed.
Staging was done by MRI in 29 patients, CT scan in
71 patients and anorectal endosonography in 56 patients
and most patients presented with T2 or T3 cancers
(TNM stage II or III), respectively. Demographic data, T
stage and TNM stage of the cohort are presented in
Table 1. Anal cancer of the outer margin was signifi-
cantly more frequent in men (p = 0.05). In contrast, can-
cer involving the anal channel tended to be more
frequent in women (n.s.).Clinical symptoms
Almost all patients reported symptoms due to anal car-
cinoma: 85 of 86 patients described at least one clinical
complaint. The mean duration of symptoms before diag-
nosis was 8 months (median 3, range 0–62 months).
The duration of the symptoms did not differ according
to any of the symptoms, the total number of symptoms
or tumor stage (not shown).Table 1 Epidemiological characteristics of our patients with
anal carcinoma
Description Numbers
Mean ± standard deviation
Gender Male: 30 (35 %)
Female: 56 (65 %)
Age 62 ± 13 years, range: 32–91 years
Diagnostic delay 8 ± 12 months, range: 0–62 months
BMI 24.7 ± 4.3 kg/m2, range: 17.3–34.7 kg/m2
Histology Squamous carcinoma: 85 (99 %)
Neuroendocrine carcinoma: 1 (1 %)
HIV Positive: 5, Negative: 1
Unknown: 80
T Stage T1: 8 (9 %)
T2: 32 (37 %)
T3: 25 (29 %)
T4: 21 (24 %)
TNM Stage Stage I: 8 (9 %)
Stage II: 27 (31 %)
Stage III: 50 (58 %)
Stage IV: 1 (1 %)







36 (42 %)Clinical symptoms are summarized in Table 2. The
most frequent symptoms were anal bleeding (78 %),
anal/perianal pain (63 %, including 29 % with anal
pain, 24 % with perianal pain and 38 % of patients with
painful defecation), weight loss (31 %), tumor on self-
palpation (26 %) and foreign body sensation (22 %).
On average, patients described 3.3 symptoms.
Clinical presentation differed according to the T-stage
of the tumor; patients with advanced disease described
significantly more symptoms (2.1 for T1 and 4.4 for T2;
p < 0.01, compare Table 2 and Fig. 1a). In addition, peri-
anal pain, constipation, abdominal pain and weight loss
were significantly more frequent in patients with locally
advanced disease. Pruritus was more prevalent in pa-
tients with early T-stages. The most common symptoms
anal bleeding and anal pain occurred with similar fre-
quency in early and advanced tumors.
Findings on physical examination
The vast majority of patients (82 out of 86) had patho-
logical findings on physical examination (Table 3). Patients
with locally advanced disease (T3 and T4) were likely to
have more findings on physical examination than those
with early disease (T1 and T2; Fig. 1b; p = 0.04). The fre-
quency of all individual physical findings was similar in all
tumor stages and no significant differences could be de-
tected. Digital rectal examination was not possible due to
pain in 2 patients, both of which presented with locally
advanced carcinomas.
Regression analysis
Multivariate logistic regression analysis was used to distin-
guish early carcinoma (T1 or T2) from locally advanced
tumor (T3 or T4) using clinical symptoms and physical
findings. We step-wise eliminated all variables which did
not significantly contribute to T-stage prediction, using
p = 0.1 as a cut-off. Our final model used 4 variables for
T-stage prediction (Table 4). Thereby, perianal pain was
the single symptom with the strongest predictive value
regarding the presence of locally advanced disease (odds
ratio 6.1, 95 %-CI 1.5–25.1, p = 0.011). In addition, painful
defecation and weight loss were able to predict locally
advanced disease.
We also tested predictability of TNM-stage by symp-
toms and findings. According to our analysis TNM-stage
could also be predicted, but with less precision (Additional
file 1: Table S1). Perianal pain was the strongest predictor
of TNM-stage, to a similar extent as described for T-stage.
Age at diagnosis
To analyze effects of the age at diagnosis we divided our
cohort into a younger (≤62 years, n = 42) and an older
age group (>62 years, n = 44; Additional file 1: Table S2).
Younger patients had a higher TNM-stage (2.7 vs. 2.3,
Table 2 Clinical symptoms of patients with various tumor stages (expressed as percent of total number of patients with respective
tumor stage). Statistical analysis: Generalized linear model
All T1 T2 T3 T4 χ2
n = 86 n = 8 n = 32 n = 25 n = 21 significance
Blood in stool 78 % 75 % 77 % 84 % 76 % 0.78
Pain Painful defecation 38 % 25 % 26 % 52 % 48 % 0.26
Anal pain 29 % 25 % 29 % 24 % 33 % 0.83
Perianal pain 24 % 0 10 % 32 % 48 % <0.01
Defecation and stool irregularities Outlet obstruction 7 % 0 3 % 12 % 10 % 0.20
Incontinence 12 % 0 6 % 16 % 19 % 0.07
Pencil stool 6 % 0 6 % 4 % 10 % 0.45
Diarrhea 11 % 0 10 % 16 % 10 % 0.50
Irregular stool 7 % 0 6 % 8 % 10 % 0.40
Constipation 6 % 0 0 8 % 14 % 0.02
Local mechanical symptoms Foreign body sensation 22 % 0 2 % 20 % 29 % 0.28
Pruritus 21 % 37 % 29 % 16 % 5 % <0.01
Tumor on self-palpation 26 % 25 % 26 % 24 % 29 % 0.81
Other organ involvement Abdominal pain 5 % 0 0 4 % 14 % 0.02
Mechanical ileus 1 % 0 0 0 5 % 0.16
Vaginal stool 1 % 0 0 0 5 % 0.16
Inguinal lymph nodes on self-palpation 2 % 0 3 % 0 5 % 0.64
Systemic symptoms/findings Weight loss 31 % 25 % 20 % 30 % 60 % <0.01
Anemia 2 % 0 0 4 % 5 % 0.22
Asymptomatic 1 % 12 % 0 0 0 0.63
Total symptoms 3.3 2.12 2.75 3.52 4.43 <0.01
Fig. 1 Relationship between the number of clinical symptoms (a) and physical findings (b) and the T-Stage of anal carcinoma. The line indicates
average number of symptoms
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Table 3 Physical findings in our patients during digital rectal examination. Statistical analysis: Generalized linear model
All T1 T2 T3 T4 χ2
n = 86 n = 8 n = 32 n = 25 n = 21 significance
Painful palpation 39 % 25 % 30 % 40 % 65 % 0.15
Resistance on palpation 88 % 50 % 90 % 100 % 90 % 0.32
Blood on palpation 31 % 14 % 29 % 36 % 40 % 0.44
No clinical findings (or normal rectal examination) 7 % 37 % 9 % 0 0 0.02
Total number of physical findings 1.60 0.87 1.68 1.76 2.09 0.04
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than the older subgroup (chance of involvement of the
proximal anal channel: 91 vs. 72 %, p = 0.044), but no
further significant differences were detected and age at
diagnosis is unlikely to confound our analysis.
Location of anal carcinoma
Combining information available from imaging (MRI, CT-
scan and endosonography) and the physical examination
we determined for each patient whether the proximal anal
channel (close to the rectum) and/or distal anal channel
(bordering the skin) was involved by the carcinoma.
Patients with proximal anal carcinoma had a higher T-
stage than patients with distal cancer (mean T-stage
2.6 vs. 1.9, p = 0.03 for distal vs. proximal anal cancer,
Additional file 1: Table S3). In addition, a description of
distal carcinoma without proximal involvement was more
frequent for localized cancers (OR for T-stage: 0.13, 95 %
CI 0.03–0.64, p = 0.012) and proximal carcinoma was more
common in locally advanced cancer (OR for T-stage: 3.0,
95 % CI 1.2–7.6, p = 0.019). However, multivariate logistic
analysis did not result in any variables with significant con-
tributions for prediction of early and advanced cancer.
Discussion
In this study we provide a comprehensive clinical
characterization of a cohort of patients with newly diag-
nosed anal carcinoma. According to our analyses, clin-
ical symptoms have predictive value for local staging of
anal carcinoma.Table 4 Predictive value of symptoms for T-stage of anal
carcinoma. The final model of our multivariate logistic regression
analysis had significant predictive value to distinguish a localized
vs. locally advanced tumor (R2 = 0.37; p = 0.03). In the table the
odds ratio (OR) of a symptom or physical finding for prediction of
locally advanced cancer (T3/T4 vs. T1/T2) are shown. Only variables
with p < 0.100 are indicated
Symptom or finding OR 95 % CI p-value
Perianal pain 6.1 1.5–25.1 0.011
Painful defecation 3.5 1.1–10.8 0.026
Weight loss 5.0 1.4–17.4 0.010
Pruritus 0.2 0.05–0.81 0.024Our study fills a gap in our knowledge since no system-
atic study regarding physical findings in anal carcinoma
has been performed. Furthermore, no contemporary study
describing the clinical presentation of anal carcinoma is
available and the incidence of anal carcinoma, the preva-
lence of risk factors and medical practice has tremendously
changed since the publication of the last paper characteriz-
ing anal carcinoma almost 30 years ago [10–14]. In agree-
ment with previous studies, bleeding, anal pain and
sensation of an anal mass remain the most frequent symp-
toms of anal carcinoma. However, the presence of anal
pain including painful defecation and perianal pain (63 vs.
20–35 %) as well as anal bleeding (77 vs. 45 %) were more
frequent than in historical studies [10–14]. In addition we
found that nearly all patients had at least one symptom
likely associated with anal carcinoma. Truly asymptomatic
anal carcinoma was exceedingly rare in our cohort (1 vs.
20 % in a previous study [10]). Pathological physical find-
ings were also almost universal and only 6 % of our
patients had a normal rectal examination.
Symptoms and findings of anal carcinoma were signifi-
cantly correlated to the T-stage of the tumor. This pre-
dictive value of the clinical presentation has not been
described previously and might be unique among gastro-
intestinal carcinomas (e.g. colon cancer, stomach cancer)
for which early symptoms or findings are rare and symp-
toms do not reflect T stage or TNM stage [16–19]. For
anal carcinoma, patients with advanced disease had a
greater number of symptoms than those with early dis-
ease. They frequently reported perianal pain, changes in
stool consistency and sometimes symptoms suggesting
involvement of neighboring organs. Thereby, the predict-
ive value of perianal pain for advanced tumor remained
strong even in a multivariate regression analysis. This
indicates that patients are able to “sense” local progression
of this tumor. The ability of a significant fraction of
patients with anal carcinoma to perceive locally advanced
disease is likely related to the somatic sensation of the anal
region, frequent mechanical stress during defecation
and functional importance of the anal region for suc-
cessful defecation. Similar to stomach and colon cancer,
duration of symptoms does not predict tumor stage
[16–18] but our study might be underpowered to detect
subtle differences.
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of a profound careful clinical history of patients with anal
carcinoma. Attention should be paid to the localization of
anal pain: According to our analysis, local anal pain or
pain at defecation was compatible with both, early and
advanced anal carcinoma. However, perianal pain (outside
the anus) was almost exclusive found in patients with
higher T-stages. Furthermore, the abundance of positive
physical findings (in 99 % of our patients) underscores the
importance of a careful examination of all patients.
Our study has limitations: i) data were collected retro-
spectively and 86 patients may be too small to detect all
relevant associations. However, a prospective study of
such a rare tumor would be difficult and the size of our
study compares favorably to historic analyses and is the
only study regarding this subject in almost 30 years. ii)
No disease control group is available and all symptoms
under discussion are not specific for anorectal cancer
and might also be caused by hemorrhoids, fissure, infec-
tious proctitis, rectal abscess, fistula or other common
conditions [3, 20–23]. Therefore, our results cannot be
used to estimate the diagnostic accuracy of individual
symptoms for anal cancer. iii) Our analyses tested the
predictive power of symptoms for T and TNM stage;
however, we did not test the predictive power of symp-
toms and findings for overall survival or disease specific
survival as hard clinical end points. Since in our follow-
up analyses only 5 patients had died of anal cancer
(not shown), our study is insufficiently powered for a
survival analysis. iv) For the majority of our patients
no result of an HIV test is available. Triemli Hospital
is not a major referral center for HIV patients. We as-
sume that for most of these patients HIV testing or at
least a risk assessment has been performed with a
negative result or a perceived low risk. Therefore, our
results might not reflect the typical presentation of an
HIV positive patient with anal carcinoma. v) No PCR
testing for HPV was performed; with this method an
HPV prevalence of 80–90 % has been described in other
cohorts [24, 25]. vi) We did not perform a population-
based study and therefore referral bias cannot be com-
pletely excluded. However, we estimate that the majority
of patients with anal cancer of the 300,000–500,000 pa-
tients of the catchment area of our hospital were referred
to the division of radiation oncology of this hospital for
palliative or definite treatment. The number of 86 patients
over a 10-year study period is in reasonable agreement
with near-complete coverage if an incidence of 1–2 cases
per 100,000 individuals is assumed [1–6].
Conclusion
In summary, our study provides a contemporary summary
of the clinical presentation of anal carcinoma. Nearly all
patients displayed symptoms including pain, bleeding andforeign body sensation and/or physical findings such as
pain on palpation, resistance and blood. Symptoms, es-
pecially pain perceived outside the anal channel, painful
defecation and weight loss had predictive value for ad-
vanced disease. Due to the high sensitivity, functional
importance and good accessibility of the anal and peri-
anal region, clinical history and physical examination
can identify patients with a high likelihood of advanced
anal cancer.
Additional file
Additional file 1: Table S1. Predictive value of symptoms for TNM-stage
of anal carcinoma (similar to T- in Table 4). The final model of our multivariate
logistic regression analysis had significant predictive value to distinguish early
from advanced cancer (R2=0.40; p=0.040).The odds ratio of a symptom or
physical finding for prediction of advanced cancer (stage III/ IV vs. stage I/ II).
Only variables with p-values less than 0.10 are shown. Table S2. Characteristics
of the older and younger subgroup of our anal carcinoma cohort. Statistical
analysis: Mann-Whitney U test. Table S3. Characteristics of patients
with involvement of the proximal (close to rectum) and distal (close to skin)
anal channel. Statistical analysis: Mann Whitney U test. (PDF 233 kb)
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